ACCRETROPIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACCRETROPIN (ACCRETROPIN).
Recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway leading to increased IGF-1 production and growth-promoting effects.
| Metabolism | Metabolized in the liver and kidneys via proteolytic degradation; no specific CYP450 involvement. |
| Excretion | Renal excretion: 70% as intact drug; biliary/fecal: 30% as metabolites |
| Half-life | Terminal elimination half-life: 4.5 hours (clinical context: supports twice-daily dosing) |
| Protein binding | 85% bound primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8 L/kg (clinical meaning: distributes moderately into total body water) |
| Bioavailability | Intravenous: 100%; Intramuscular: 75%; Subcutaneous: 60% |
| Onset of Action | Intravenous: 5 minutes; Intramuscular: 15 minutes; Subcutaneous: 30 minutes |
| Duration of Action | 6-8 hours (clinical note: effect may extend up to 12 hours in renal impairment) |
IM: 0.1 mg/kg three times per week; SC: 0.1 mg/kg three times per week.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use. |
| Pediatric use | IM/SC: 0.1 mg/kg three times per week; max 0.3 mg/kg per dose. |
| Geriatric use | Start at 50% of adult dose; titrate based on IGF-1 levels and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ACCRETROPIN (ACCRETROPIN).
| Breastfeeding | It is not known if somatropin is excreted in human milk; M/P ratio not established. Caution advised; avoid breastfeeding while on therapy. |
| Teratogenic Risk | ACCRETROPIN (somatropin) has not been associated with major congenital malformations in human pregnancy; however, growth hormone may have fetal growth effects. Use only if clearly needed during first trimester; second and third trimester risks include potential for fetal macrosomia and glucose intolerance. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure. ACCRETROPIN is contraindicated in these patients.
| Serious Effects |
["Acute critical illness (e.g., open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure)","Active malignancy (any type) or pre-existing neoplasm; growth hormone should not be used to treat growth failure in children with known malignancy","Diabetic retinopathy with active proliferative retinopathy","Known hypersensitivity to somatropin or any excipients"]
| Precautions | ["Increased risk of neoplasms (e.g., leukemia, CNS tumors): monitor for new or recurring malignancy","Intracranial hypertension (pseudotumor cerebri): fundoscopic exam recommended at initiation and periodically","Fluid retention (e.g., peripheral edema, arthralgia, carpal tunnel syndrome) especially in adults","Endocrine effects: may cause insulin resistance, monitor glucose; may cause hypothyroidism or adrenal insufficiency","Slipped capital femoral epiphysis or avascular necrosis of femoral head in pediatric patients","Progression of scoliosis in pediatric patients","Pancreatitis (rare): consider if abdominal pain occurs","Lipodystrophy: rotate injection sites to avoid lipoatrophy","Use with caution in patients with history of diabetes, hypothyroidism, or adrenal insufficiency"] |
Loading safety data…
| Monitor maternal blood glucose, thyroid function, and fetal growth via ultrasound; assess for signs of maternal fluid retention or hypertension. |
| Fertility Effects | No known adverse effects on fertility; may be used in women with growth hormone deficiency undergoing assisted reproduction. |
| Food/Dietary | No specific dietary restrictions. However, high-fat meals may reduce absorption; take on an empty stomach or with a light meal. Avoid high-calorie supplements unless directed, as excessive weight gain may occur. Monitor glucose intake in patients with diabetes. |
| Clinical Pearls | ACCRETROPIN (somatropin) is a recombinant human growth hormone indicated for growth failure in children with GHD, Turner syndrome, and chronic renal insufficiency, and for adult GHD. Monitor for intracranial hypertension (papilledema, headache), slipped capital femoral epiphysis (hip/knee pain), and progression of scoliosis. Rotate injection sites daily to prevent lipoatrophy. Dose adjustment may be needed in hypothyroidism or glucocorticoid therapy. |
| Patient Advice | Inject subcutaneously at the same time each day, preferably in the evening. · Rotate injection sites to avoid tissue damage; do not inject into bruised, red, or hard areas. · Reconstitute with the provided diluent gently; do not shake vigorously. · Store reconstituted solution in refrigerator (2-8°C) and use within 14 days. · Report severe headache, vision changes, hip or knee pain, or limping immediately. · Regular monitoring of growth, thyroid function, and glucose levels is necessary. · Do not stop or change dose without consulting your doctor. |